Vanderbilt University Medical Center - Vanderbilt Launches New Genetic Screening Program to Prevent Problems Associated with Plavix, the Most Commonly Prescribed Clot-Preventing Drug for Heart Patients

Links shared publicly online about this topic.

841
total visits

Vanderbilt University Medical Center - Vanderbilt Launches New Genetic Screening Program to Prevent Problems Associated with Plavix, the Most Commonly Prescribed Clot-Preventing Drug for Heart Patients

Beginning this month, all patients undergoing cardiac catheterization at Vanderbilt University Medical Center will be tested for a genetic variation that can affect their response to Plavix, the most commonly prescribed clot-preventing drug for heart patients and one of the most commonly prescribed drugs worldwide.

View full resource at mc.vanderbilt.edu

Tags: Heart, Genetic, Drug, Anti-Clotting Medication, Plavix, Vanderbilt University Medical Center